Table 4.
Comparison of IGH-rearranged B-ALL from literature to t(5;14)(q31;q32); IGH-IL3 B-ALL (our series plus published cases).
| IGH patients* | IGH-IL3 patients | Age at diagnosis (median) [range] | Male to female ratio | White blood cells (x109/L) | IKZF1 deletion | Additional cytogenetic abnormalities | ||
|---|---|---|---|---|---|---|---|---|
| This study** | All patients | 24 | 24/24 (100%) |
14.3 years [4–60 years] |
20/4 | <50: 9/21 (43%) >50: 12/21 (57%) |
5/7 (71%) | 9/23 (39%) |
| 0–19 years-old | 17 | 17/17 (100%) |
11 years [4–19 years] |
14/3 | <50: 3/17 (18%) >50: 14/17 (82%) |
3/4 (75%) | 4/18 (22%) | |
| 20–60 years-old | 7 | 7/7 (100%) |
33 years [22–60 years] |
6/1 | <50: 6/6 (100%) >50: 0/6 (0%) |
2/2 (100%) |
5/7 (71%) | |
| Russell et al. (9) | UKALL2003 | 103/2,572 (4%) |
0/2,572 (0%) |
5 years [1–24 years] |
1.6/1 | <50: 80/103 (78%) >50: 23/103 (22%) |
21/58 (36%) |
89/143 (62%) |
| UKALLXII | 56/697 (8%) |
0/697 (0%) |
33 years [15–64 years] |
1.2/1 | <50: 39/55 (71%) >50: 16/55 (29%) |
14/30 (47%) |
||
| Chapiro et al. (12) | 29/4,362 (0.6%) | 0/4,362 (0%) | 25 years [5–85 years] | 1.4/1 | NS | NS | 19/29 (66%) | |
| Lafage-Pochitaloff et al. (41) | 27/542 (5%) |
0/542 (0%) |
43 years [18–59 years] |
0.6/1 | <30: 23/27 (85%) >30: 4/27 (15%) |
NS | 22/27 (81%) | |
*
Incidence as determined by IGH FISH and/or 14q32 translocations.
**
Our series (n = 8) plus published cases (n = 16).
Some data were not evaluable for all published cases, explaining a variable denominator.
5y EFS, 5-year event-free survival; 5y OS, 5-year overall survival; CI, Confidence interval; NS, Not specified.